• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

度洛西汀可减轻灼口综合征和非典型牙痛患者的疼痛,并伴有血小板5-羟色胺转运体下调。

Duloxetine attenuates pain in association with downregulation of platelet serotonin transporter in patients with burning mouth syndrome and atypical odontalgia.

作者信息

Nakamura Mariko, Yoshimi Akira, Mouri Akihiro, Tokura Tatsuya, Kimura Hiroyuki, Kishi Shinichi, Miyauchi Tomoya, Iwamoto Kunihiro, Ito Mikiko, Sato-Boku Aiji, Ozaki Norio, Nabeshima Toshitaka, Noda Yukihiro

机构信息

Division of Clinical Sciences and Neuropsychopharmacology, Graduate School of Pharmacy, Meijo University, Nagoya, Japan.

Clinical OMICs and Translation Research Center, Meijo University, Nagoya, Japan.

出版信息

Hum Psychopharmacol. 2022 Mar;37(2):e2818. doi: 10.1002/hup.2818. Epub 2021 Sep 20.

DOI:10.1002/hup.2818
PMID:34541697
Abstract

OBJECTIVE

The aim of this study was evaluation of the association between severity of pain and expression of total or ubiquitinated serotonin transporter (SERT) protein in patients with burning mouth syndrome and atypical odontalgia (BMS/AO), who were treated by duloxetine.

METHODS

Patients with BMS/AO were assessed for severity of pain using the visual analog scale (VAS), and expression of total and ubiquitinated SERT protein in platelets before (baseline) and 12 weeks after duloxetine-treatment.

RESULTS

The expression of total and ubiquitinated SERT protein at baseline in all patients (n = 33) were higher and lower, respectively, compared to those in healthy controls. 12 weeks after duloxetine-treatment, there was no difference in the total SERT protein levels between patients (n = 21) and healthy controls. In the 16 patients who could be measured, mean VAS scores and total SERT protein levels were significantly decreased after the treatment, compared to those at baseline. There was tendency for a positive correlation between total SERT protein levels and VAS scores in these patients.

CONCLUSIONS

Our findings indicate that duloxetine relieves pain in association with downregulation of platelet SERT expression in patients with BMS/AO.

摘要

目的

本研究旨在评估接受度洛西汀治疗的灼口综合征和非典型牙痛(BMS/AO)患者的疼痛严重程度与血清素转运体(SERT)总蛋白或泛素化蛋白表达之间的关联。

方法

使用视觉模拟量表(VAS)评估BMS/AO患者的疼痛严重程度,并在度洛西汀治疗前(基线)和治疗12周后检测血小板中SERT总蛋白和泛素化蛋白的表达。

结果

与健康对照组相比,所有患者(n = 33)基线时SERT总蛋白和泛素化蛋白的表达分别更高和更低。度洛西汀治疗12周后,患者(n = 21)与健康对照组之间的SERT总蛋白水平无差异。在可测量的16例患者中,治疗后的平均VAS评分和SERT总蛋白水平与基线时相比显著降低。这些患者的SERT总蛋白水平与VAS评分之间存在正相关趋势。

结论

我们的研究结果表明,度洛西汀可通过下调BMS/AO患者血小板SERT表达来缓解疼痛。

相似文献

1
Duloxetine attenuates pain in association with downregulation of platelet serotonin transporter in patients with burning mouth syndrome and atypical odontalgia.度洛西汀可减轻灼口综合征和非典型牙痛患者的疼痛,并伴有血小板5-羟色胺转运体下调。
Hum Psychopharmacol. 2022 Mar;37(2):e2818. doi: 10.1002/hup.2818. Epub 2021 Sep 20.
2
Duloxetine improves chronic orofacial pain and comorbid depressive symptoms in association with reduction of serotonin transporter protein through upregulation of ubiquitinated serotonin transporter protein.度洛西汀通过上调泛素化血清素转运蛋白,降低血清素转运蛋白水平,从而改善慢性口面部疼痛和共病抑郁症状。
Pain. 2024 May 1;165(5):1177-1186. doi: 10.1097/j.pain.0000000000003124. Epub 2024 Jan 11.
3
Duloxetine Plasma Concentrations and Its Effectiveness in the Treatment of Nonorganic Chronic Pain in the Orofacial Region.度洛西汀血浆浓度及其在治疗口面部区域非器质性慢性疼痛中的有效性。
Clin Neuropharmacol. 2017 Jul/Aug;40(4):163-168. doi: 10.1097/WNF.0000000000000225.
4
Evaluating Burning Mouth Syndrome as a Comorbidity of Atypical Odontalgia: The Impact on Pain Experiences.评估灼口综合征作为非典型性牙痛的共病:对疼痛体验的影响。
Pain Pract. 2018 Jun;18(5):580-586. doi: 10.1111/papr.12647. Epub 2017 Nov 20.
5
Duloxetine in the treatment of burning mouth syndrome refractory to conventional treatment: A case report.度洛西汀治疗常规治疗无效的灼口综合征:一例报告
J Int Med Res. 2014 Jun;42(3):879-83. doi: 10.1177/0300060514527913. Epub 2014 Apr 17.
6
Relationship between serotonin transporter occupancies and analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine in reserpine-induced myalgia rats.在利血平诱导的肌痛大鼠中,5-羟色胺转运体占有率与吲哚洛辛的(+)-异构体AS1069562及度洛西汀镇痛作用之间的关系。
Neuroscience. 2015 Mar 19;289:262-9. doi: 10.1016/j.neuroscience.2014.12.065. Epub 2015 Jan 13.
7
Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region.抗抑郁治疗对以口面部周围疼痛为主的躯体症状障碍患者血浆中神经炎症相关分子水平的影响。
Hum Psychopharmacol. 2019 Jul;34(4):e2698. doi: 10.1002/hup.2698. Epub 2019 May 24.
8
Burning mouth syndrome responsive to duloxetine: a case report.伴有口干的灼口综合征对度洛西汀有反应:一例报告。
Pain Med. 2011 Mar;12(3):466-9. doi: 10.1111/j.1526-4637.2010.01035.x. Epub 2011 Jan 11.
9
Effectiveness of duloxetine for the treatment of chronic nonorganic orofacial pain.度洛西汀治疗慢性非器质性口面部疼痛的有效性。
Clin Neuropharmacol. 2012 Nov-Dec;35(6):273-7. doi: 10.1097/WNF.0b013e31827453fa.
10
Sore Mouth.
Am J Med. 2021 Apr;134(4):e270. doi: 10.1016/j.amjmed.2020.08.031. Epub 2020 Sep 28.

引用本文的文献

1
Managing Burning Mouth Syndrome: Current and Future Directions.灼口综合征的管理:现状与未来方向
Drugs. 2025 Aug 15. doi: 10.1007/s40265-025-02220-x.
2
The Usefulness of the Short Form-8 for Chronic Pain in the Orofacial Region: A Prospective Cohort Study.简化版面部疼痛量表-8用于口面部慢性疼痛的有效性:一项前瞻性队列研究。
Cureus. 2023 Sep 20;15(9):e45586. doi: 10.7759/cureus.45586. eCollection 2023 Sep.